RxDoctor Payments Data

Jerry Twiggs

Adolescent Medicine · St. George, UTNPI 1972583680

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (47.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by AstraZeneca at 59.3% of the total. Reporting peaked in 2019 at $2,143 and has fallen 96.0% since, to $85 in 2025.

$2,929in general payments, 2019–2025

Across 69 payments — averaging $42.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Shire North American Group Inc$330
  • Ironshore Pharmaceuticals Inc.$218
  • Pfizer$105
  • Takeda Pharmaceuticals U.S.A., Inc.$83
  • Neurelis, Inc.$77
  • plus $377 from 11 others
$840,261in research payments, 2019–2025

Across 121 payments — averaging $6944.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$434K
  • Pfizer$207K
  • Astrazeneca UK Limited$165K
  • GSK$23K
  • Purdue Pharma L.p.$8K
  • Merck$4K

What the payments were for

  • Consulting fees$33011%
  • Travel & lodging$1,37947%
  • Food & beverage$1,22042%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few adolescent medicine providers in Utahto place this figure against a meaningful peer group, so we don't.

Other adolescent medicine in St. George

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →